MICROSTRUCTURE OF BIOPOLYMER MICRO-FIBROUS SCAFFOLD AND ITS INFLUENCE ON THE ABILITY TO RETAIN MEDICINES AND TISSUE REGENERATION.

The aim of the research is to study the microstructure, antibiotic-absorbing and framework capacity of the fibrous non-woven PCL matrices designed by us for the regeneration of tissues and capillaries. Samples of microfibrous non-woven matrices made by our technology out of polycaprolactone PCL (invention patent of Ukraine № 119958) were used in the work. Antibiotic retention in samples of matrix materials was evaluated during the 1st, 3rd, 5th, 7th, 14th, 18th and 21st days of the experiment. The experimental part of the research was performed using 30 laboratory animals (rabbits). On the basis of microscopic studies of the biopolymer microfiber matrices obtained by us, the relationship between the increase in polymer concentration in the sucrose melt and the increase in the percentage of thicker microfibers was determined. Microbiological analysis of the antibiotic-absorbing capacity of the obtained microfibrous biopolymer non-woven matrices determined that lincomycin impregnated into polymer matrices is characterized by less stability during storage than cefazolin. Antibiotic concentrations of the impregnated matrix material samples were actively maintained at the level of control values for a period of 5 days. The pathomorphological analysis of soft tissues at all times of subcutaneous implantation in the experiment made it possible to determine the fact of regeneration of tissues and the microcirculatory channel through the entire thickness of the fibrous matrix. This was confirmed by a significant decrease in the area of the connective tissue matrix per vessel from (49345.18+485.63) µm2 to (24797.47+480.28) µm2, an increase in the cross-sectional area of vessels from (697.61+21.79) µm2 to (1321.23+24.82) µm2 and a decrease in the thickness of vascular walls from (3.2+0.05) µm to (2.65+0.07) µm (p<0.01) from the periphery to the center of the frame. These facts, in our opinion, confirm the framework function of the polymer matrix synthesized by us, which is also a means of one-time local delivery of the medicine to the tissues in the damaged area.

Granulosa and theca cell tumor in rat's ovary after modified Biskind operation.

BACKGROUND: Earlier, we described morphological changes in rat ovaries in different terms after Biskind's operation elucidating the factors that affect the precancerous conditions and ovarian neoplasms appearance. The aim of the research was to identify tumor nature on the 120th day after modified Biskind's operation using immunohistochemical approach. RESULTS: We described morphological changes in rat ovaries on the 120th day after Biskind's operation, demonstrated development of theca-granulosa cell tumors, and differentiated between Sertoli-Leydig cell tumors and theca-granulosa cell tumors using monoclonal antibodies against Ingibin-alfa, Calretinin, Melan А. CONCLUSION: Modified Biskind's model could be used to study sex-cord tumors in rat ovaries.

Improvement of the complex medical treatment for the patients wіth chronic biliary pancreatitis.

INTRODUCTION: The most common reason of chronic pancreatitis is liver and bile ducts disease: functional disorders, chronic cholecystitis, cholelithiasis and cholecystectomy in medical history. All these changes are associated with the colloidal structure of bile, increased lithogenicity, gallstones formation, Oddi's sphincter dysfunction, dysmotility and inflammation in the bile ducts. THE AIM: to study the effectiveness of using medicine Liveria IC (metadoxine) in standard therapy as well as effect on spectrum of blood serum lipids and structural condition of liver (stiffness) and pancreas in patients with chronic biliary pancreatitis combined with obesity. MATERIALS AND METHOD: 115 patients suffering from chronic biliary pancreatitis and obesity were the subjects of the study. They were compared to etiological factor socioeconomic conditions and nutrition (regular food 5 times a day without aggressive food (fatty, spicy, sour, fried products)). Also the effect of the alcohol factor was excluded. RESULTS: The obtained decrease in stiffness of the liver and pancreas indicates an improvement of their structural state. CONCLUSIONS: Using medication LiveriaIC (metadoxine) as the part of the complex therapy for the patients who are suffering from CBP combined with obesity gives some improvement of the lipid profile indices and the structural condition of liver and pancreas (according to the data of SWE) (р<0.05).

A clinically applicable molecular-based classification for endometrial cancers.

BACKGROUND: Classification of endometrial carcinomas (ECs) by morphologic features is inconsistent, and yields limited prognostic and predictive information. A new system for classification based on the molecular categories identified in The Cancer Genome Atlas is proposed. METHODS: Genomic data from the Cancer Genome Atlas (TCGA) support classification of endometrial carcinomas into four prognostically significant subgroups; we used the TCGA data set to develop surrogate assays that could replicate the TCGA classification, but without the need for the labor-intensive and cost-prohibitive genomic methodology. Combinations of the most relevant assays were carried forward and tested on a new independent cohort of 152 endometrial carcinoma cases, and molecular vs clinical risk group stratification was compared. RESULTS: Replication of TCGA survival curves was achieved with statistical significance using multiple different molecular classification models (16 total tested). Internal validation supported carrying forward a classifier based on the following components: mismatch repair protein immunohistochemistry, POLE mutational analysis and p53 immunohistochemistry as a surrogate for 'copy-number' status. The proposed molecular classifier was associated with clinical outcomes, as was stage, grade, lymph-vascular space invasion, nodal involvement and adjuvant treatment. In multivariable analysis both molecular classification and clinical risk groups were associated with outcomes, but differed greatly in composition of cases within each category, with half of POLE and mismatch repair loss subgroups residing within the clinically defined 'high-risk' group. Combining the molecular classifier with clinicopathologic features or risk groups provided the highest C-index for discrimination of outcome survival curves. CONCLUSIONS: Molecular classification of ECs can be achieved using clinically applicable methods on formalin-fixed paraffin-embedded samples, and provides independent prognostic information beyond established risk factors. This pragmatic molecular classification tool has potential to be used routinely in guiding treatment for individuals with endometrial carcinoma and in stratifying cases in future clinical trials.

Genomic analysis of genetic heterogeneity and evolution in high-grade serous ovarian carcinoma.

Resistance to chemotherapy in ovarian cancer is poorly understood. Evolutionary models of cancer predict that, following treatment, resistance emerges either because of outgrowth of an intrinsically resistant sub-clone or evolves in residual disease under the selective pressure of treatment. To investigate genetic evolution in high-grade serous (HGS) ovarian cancers, we first analysed cell line series derived from three cases of HGS carcinoma before and after platinum resistance had developed (PEO1, PEO4 and PEO6; PEA1 and PEA2; and PEO14 and PEO23). Analysis with 24-colour fluorescence in situ hybridisation and single nucleotide polymorphism (SNP) array comparative genomic hybridisation (CGH) showed mutually exclusive endoreduplication and loss of heterozygosity events in clones present at different time points in the same individual. This implies that platinum-sensitive and -resistant disease was not linearly related, but shared a common ancestor at an early stage of tumour development. Array CGH analysis of six paired pre- and post-neoadjuvant treatment HGS samples from the CTCR-OV01 clinical study did not show extensive copy number differences, suggesting that one clone was strongly dominant at presentation. These data show that cisplatin resistance in HGS carcinoma develops from pre-existing minor clones but that enrichment for these clones is not apparent during short-term chemotherapy treatment.